Evaluation of relationship between cytokine and chemokine levels measured by using multiplex laboratory method before and after treatment and clinical course and treatment response in rheumathoid arthritis patients receiving TNF- and #945; blocker therapy

Bulur, Atilla; Erden, A.; İnanç, Nevsun

doi:10.5455/annalsmedres.2019.05.251

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, several studies showed the capacity of biological therapies to reduce the protein levels of different cytokines and adhesion molecules. Bulur A. et al reported that after 6 months of treatment with anti-TNF therapy including infliximab, adalimumab and etanercept, the serum levels of IL10, IL-12p40, IFN-and macrophage chemoattractant protein-1 (MCP-1) were reduced [33]. In line with this, Charles P. et al demonstrated that the treatment with infliximab decreased the serum levels of IL-6, IL-1, GM-CSF, IL-8, p55 sTNFR in 73 RA patients after four weeks of treatment [34].…”

Section: Biological Dmards As Effective Therapies To Reduce Inflammation and Articular Damagementioning

confidence: 99%

Effects of Biological Therapies on Molecular Features of Rheumatoid Arthritis

López‐Pedrera

Barbarroja

Patiño-Trives

et al. 2020

IJMS

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is an autoimmune and chronic inflammatory disease primarily affecting the joints, and closely related to specific autoantibodies that mostly target modified self-epitopes. Relevant findings in the field of RA pathogenesis have been described. In particular, new insights come from studies on synovial fibroblasts and cells belonging to the innate and adaptive immune system, which documented the aberrant production of inflammatory mediators, oxidative stress and NETosis, along with relevant alterations of the genome and on the regulatory epigenetic mechanisms. In recent years, the advances in the understanding of RA pathogenesis by identifying key cells and cytokines allowed the development of new targeted disease-modifying antirheumatic drugs (DMARDs). These drugs considerably improved treatment outcomes for the majority of patients. Moreover, numerous studies demonstrated that the pharmacological therapy with biologic DMARDs (bDMARDs) promotes, in parallel to their clinical efficacy, significant improvement in all these altered molecular mechanisms. Thus, continuous updating of the knowledge of molecular processes associated with the pathogenesis of RA, and on the specific effects of bDMARDs in the correction of their dysregulation, are essential in the early and correct approach to the treatment of this complex autoimmune disorder. The present review details basic mechanisms related to the physiopathology of RA, along with the core mechanisms of response to bDMARDs.

show abstract

Section: Biological Dmards As Effective Therapies To Reduce Inflammation and Articular Damagementioning

confidence: 99%